Role of cilostazol in the sequential therapeutic spectrum of the peripheral arterial occlusion disease (PAOD);Die Rolle von Cilostazol im sequenziellen Therapiespektrum der peripheren arteriellen Verschlusskrankheit (pAVK)

Deutsche Medizinische Wochenschrift

Volumn 137, Issue 20, 2012, Pages 1051-1055

  Weber, T ^a   Meyer, F ^a   Weber, M ^a   Halloul, Z ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

cAMP; cardiovascular risk factors; inhibition of platelet aggregation; peripheral arterial occlusion disease (PAOD); quality of life; walking distance; walking exercise

Indexed keywords

CILOSTAZOL; CLOPIDOGREL; DILTIAZEM; OMEPRAZOLE; SIMVASTATIN;

ANGINA PECTORIS; ARTICLE; CEREBROVASCULAR ACCIDENT; DIARRHEA; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; FACE EDEMA; HEADACHE; HEART INFARCTION; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; INTERMITTENT CLAUDICATION; NAUSEA; PERIPHERAL EDEMA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACODYNAMICS; PRURITUS; RASH; RISK FACTOR; RISK REDUCTION; TACHYCARDIA; THROMBOCYTE AGGREGATION INHIBITION; VERTIGO; VOMITING;

ARTERIAL OCCLUSIVE DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; GERMANY; HUMANS; PERIPHERAL ARTERIAL DISEASE; PHOSPHODIESTERASE 3 INHIBITORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 84861094248     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0031-1298949     Document Type: Article

References (39)

1. Adam DJ, Beard JD, Cleveland T et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet: 2005; 366 1925 1934 (Pubitemid 41713982)
2. Adler AI, Stevens RJ, Neil A et al. UKPDS 59: Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care: 2002; 25 894 899 (Pubitemid 41094289)
3. Amendt K. PGE1 and other prostaglandins in the treatment of intermittent claudication: a meta-analysis. Angiology: 2005; 56 409 415 (Pubitemid 41040526)
4. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J: 2002; 324 71 86
5. Beebe HG, Dawson DL, Cutler BS et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med: 1999; 159 2041 2050 (Pubitemid 29453592)
6. Cone J, Wang S, Tandon F et al. Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells. J Cardiovasc Pharmacol: 1999; 34 497 504 (Pubitemid 29446916)
7. Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med: 2000; 109 523 530
8. Dawson DL, Cutler BS, Meissner MH et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation: 1998; 98 678 686 (Pubitemid 28387495)
9. de la Haye R, Diehm C, Blume J et al. Eine epidemiologische Untersuchung zur Einsetzbarkeit und zu den Grenzen der physikalischen Therapie/ Bewegungstherapie bei der arteriellen Verschlusskrankheit im Stadium II nach Fontaine. Vasa: 1992; 38 5 40
10. Deutsche Gesellschaft für Angiologie Gesellschaft für Gefäßmedizin Leitlinien zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (PAVK). Stand: 01. März 2009 http://www.awmf.org/leitlinien/detail/ll/065-003.html (11. 08. 2011)
11. Diehm C, Allenberg J-R, Haberl R et al. High all-cause mortality in patients with peripheral arterial disease in primary care: Five-year results of the getABI Study. [abstract 3701]. Circulation: 2007; 116 (16-MeetingAbstracts): II-841b
12. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ et al. Coronary stent restenosis in patients treated with cilostazol. Circulation: 2005; 112 2826 2832 (Pubitemid 41641677)
13. Elam MB, Heckman J, Crouse JR et al. Effect of the novel antiplatelet agent cilostazol on lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol: 1998; 18 1942 1947 (Pubitemid 28565758)
14. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet: 2003; 360 7 22
15. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A study in long-term effects). J Vasc Surg: 2008; 47 330 336
16. Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC / AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremities, renal, mesenteric, and abdominal aortic). Circulation: 2006; 113 e463 e465
17. Inoue T, Uchida T, Sakuma M et al. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol: 2004; 44 1408 1414 (Pubitemid 39303941)
18. Jorenby DE, Leischow SJ, Nides MA et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med: 1999; 340 685 691 (Pubitemid 29110752)
19. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk: 1994; 1 333 339
20. Lee S W, Park S W, Kim Y H et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol: 2007; 100 1103 1108
21. Mehler PS, Coll JR, Estacio R et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation: 2003; 107 753 756 (Pubitemid 36222605)
22. Meyer F, Graf D, Weber M et al. Interimsanalyse einer prospektiven Beobachtungsstudie zur Anwendung von Cilostazol (Pletal) in täglicher klinisch-gefäßchirurgischer Praxis - signifikante Verbesserung von Gehstrecke und Lebensqualität bei Patienten mit peripher arterieller Verschlusskrankheit (pAVK) Stadium IIb, jedoch nicht bei Rauchern, auch im gefäßchirurgischen Klientel. Zentralbl Chir: 2011; 136 436 443
23. Money SR, Herd JA, Isaacsohn JL et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg: 1998; 27 267 274
24. Nakamura N, Osawa H, Yamabe H et al. Effects of cilostazol on lipid and fatty acid metabolism. Clin Exp Med: 2005; 4 170 173 (Pubitemid 40562034)
25. Norgren L, Hiatt WR, Dormandy JA et al. Inter-Society consensus for the management of peripheral arterial disease (TASC II). Eur J Endovasc Surg: 2007; 33 1 75
26. Packer M, Carver JR, Rodeheffer RJ. The PROMISE Study Research Group et al. Effect of oral milrinone on mortality in sever chronic heart failure. N Engl J Med: 1991; 325 1468 1475
27. Pratt CM, Camerota AJ. New therapeutic options in the management of claudication. Am J Cardiol (Suppl): 2001; 87 1D 43D
28. Regensteiner JG, Ware JE Jr, NcCarthy WJ et al. Effect of cilostazol on treadmill walking, community based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc: 2002; 12 1939 1946 (Pubitemid 35462438)
29. Robless P, Mikhailidis D, Stansby G. Cilostazol for peripheral arterial disease. Cochrane Databas Syst: 2008; Rev 1: CD003748
30. Samra SS, Bajaj P, Vijayaraghavan KS et al. Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication. J Indian Med Assoc: 2003; 101 561 564 (Pubitemid 39214541)
31. Schrör K. Cilostazol - ein neuer Ansatz zur Behandlung von pAVK. Vasomed: 2007; 19 112 116 (Pubitemid 47055864)
32. Soga Y, Iida O, Hirano K et al. Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia. J Vasc Surg: 2011; 26 Aug
33. Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R. ScHARR: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease - Assessment Report.Stand 21. Okt. 2010; http://www.nice.org.uk/ nicemedia/live/12265/51580/51580.pdf
34. Strandness DE Jr, Dalman RL, Panian S et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovasc Surg: 2002; 36 83 91 (Pubitemid 35278404)
35. Tamhane U, Meier P, Chetcuti S et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a metaanalysis of randomised controlled trials. EuroIntervention: 2009; 5 384 393
36. Thompson PD, Zimet R, Forbes WP et al. Meta-analysis of results from eight randomizes, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol: 2002; 90 1314 1319 (Pubitemid 35449476)
37. UCB Pharma GmbH Otsuka Pharmaceutical Europe Ltd. Pletal 50/100mg Tabletten. Fachinformation Dezember 2010 http://www.pletal.de/pdf/gi-pletal-100- mg.pdf
38. Watson L, Ellis B, Leng GC. Exercise for intermittent claudicatio. Cochrane Database Syst Rev: 2008; 04: CD 000990
39. Wilhite DB, Comerota AJ, Schmieder FA et al. Managing of PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg: 2003; 38 710 713 (Pubitemid 37254796)